



## Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

August 29, 2023 12:30 PM EDT

WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- [Prelude Therapeutics Incorporated](#) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows:

### Wells Fargo 18<sup>th</sup> Annual Healthcare Conference Boston

**Kris Vaddi, Ph.D.**, Chief Executive Officer will participate in a Fireside chat on **Wednesday, September 6, at 4:30 p.m. ET**. The live webcast is available [here](#). Dr. Vaddi and **Laurent Chardonnet, Chief Financial Officer of Prelude**, will host one-on-one meetings at the conference.

### H. C. Wainwright 25<sup>th</sup> Annual Healthcare Investment Conference

**Dr. Vaddi and Jane Huang, MD, President and Chief Medical Officer** will participate in a Fireside chat on **Monday, September 11, at 1:30 p.m. ET**. The live webcast is available [here](#). Dr. Vaddi, along with Dr. Huang and Mr. Chardonnet will host one-on-one investor meetings at the conference.

### Morgan Stanley 21<sup>st</sup> Annual Global Healthcare Conference

On **Tuesday, September 12, at 4:55 p.m. ET, Dr. Vaddi and Dr. Huang** will participate in a Fireside chat. The live webcast is available [here](#). Dr. Vaddi, Dr. Huang and Mr. Chardonnet will conduct one-on-one investor meetings at the conference.

### About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company's diverse pipeline is comprised of highly differentiated, potentially best/first-in-class proprietary small molecule compounds aimed at addressing specific pathways for cancers with selectable underserved patients. Prelude's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor, PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, and a preclinical oral candidate targeting SMARCA2.

For more information, visit our [website](#) and follow us on [LinkedIn](#) and [Twitter](#).

### Investor Contact:

Lindsey Trickett  
Vice President, Investor Relations  
240.543.7970  
[ltrickett@preludetx.com](mailto:ltrickett@preludetx.com)

### Media Contact:

Helen Shik  
Shik Communications  
617.510.4373  
[helen@shikcommunications.com](mailto:helen@shikcommunications.com)